These findings emphasise the impact of AML on monocytes and DCs and suggest that the number of CD14+ monocytes, DCs, and CNVs can be used in tandem to assess AML clinical status during chemotherapy. This evidence concerns the gene CD14 and acute myeloid leukemia.